

# MART-1 Cocktail

Concentrated and Prediluted Monoclonal Antibody  
901-077-071522

**BIOCARE**  
M E D I C A L

Available Product Formats				
Format	Catalog Number	Description	Dilution	Diluent
Q Series— For Leica BOND-III	ALI 077 G7	7.0 mL	Ready-to-use	N/A

## Intended Use:

For In Vitro Diagnostic Use

MART-1 Cocktail [M2-7C10 + M2-9E3] is a mouse monoclonal antibody cocktail that is intended for laboratory use in the qualitative identification of MART-1 protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

## Summary and Explanation:

The MART-1/Melan A recognizes a protein of 18 kDa, identified as MART-1 (Melanoma Antigen Recognized by T cells 1) or Melan-A. The MART-1 recognizes a subcellular fraction found in melanosomes. The antibody labels melanomas and tumors showing melanocytic differentiation. It does not mark neoplasms of epithelial origin, lymphomas or mesenchymal tumors. MART-1 is a useful addition to melanoma panels which are specific to melanocytic lesions. Both HMB-45 and MART-1 are coexpressed in the majority of melanomas, as well as solely expressed in certain cases. Studies have shown that MART-1 is more sensitive than HMB-45 when labeling metastatic melanomas.

## Principle of Procedure:

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a one- or two-step detection procedure can be employed. The one-step procedure will feature an enzyme-labeled polymer that binds to the primary antibody. A two-step procedure will feature a secondary antibody added to bind to the primary antibody. An enzyme-labeled polymer is then added to bind to the secondary antibody. These detections of the bound antibodies are evidenced by a colorimetric reaction

**Source:** Mouse monoclonal

**Species Reactivity:** Human; others not tested

**Clone:** M2-7C10 + M2-9E3

**Isotype:** IgG2b + IgG2b

**Protein Concentration:** Call for lot specific Ig concentration.

**Epitope/Antigen:** MART-1

**Cellular Localization:** Cytoplasmic

**Positive Tissue Control:** Melanoma

**Known Applications:**

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

**Supplied As:** Buffer with protein carrier preservative

**Storage and Stability:**

Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

## Protocol Recommendations (Q Series – For Leica BOND-III):

ALI077 is intended for use with the Leica BOND-III. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

**Protocol Name:** IHC Protocol F

**Detection:** Bond Polymer Refine

**HIER:** 20 min with ER1

**Peroxide Block:** 5 min

**Marker (Primary Antibody):** 15 min

**Post Primary:** 8 min

**Polymer:** 8 min

**Mixed DAB Refine:** 10 min

**Hematoxylin:** 5 min

## Limitations:

The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions.

## Quality Control:

Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2). CLSI Wayne, PA, USA ([www.clsi.org](http://www.clsi.org)). 2011

## Precautions:

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN<sub>3</sub>) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (4)

2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (5)

3. Microbial contamination of reagents may result in an increase in nonspecific staining.

4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.

5. Do not use reagent after the expiration date printed on the vial.

6. The SDS is available upon request and is located at <http://biocare.net>.

## Troubleshooting:

Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.



60 Berry Drive  
Pacheco, CA 94553  
USA



TP v1 (10/26/2021)

Tel: 800-799-9499 | [www.biocare.net](http://www.biocare.net) | Fax: 925-603-8080

## MART-1 Cocktail

Concentrated and Prediluted Monoclonal Antibody  
901-077-071522

**BIOCARE**  
M E D I C A L

### References:

1. Orchard GE. Melan A (MART-1): a new monoclonal antibody for malignant melanoma diagnosis. *Br J Biomed Sci.* 1998 Mar; 55(1):8-9.
2. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody Melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. *Histopathology.* 1998 Feb; 32(2):139-46.
3. Kageshita T, *et al.* Differential expression of MART-1 in primary and metastatic melanoma lesions. *J Immunother.* 1997 Nov; 20(6):460-5.
4. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
5. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

Q Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Leica Biosystems. Biocare and Leica Biosystems are not affiliated, associated or related in any way. Leica, Leica Biosystems, BOND-MAX and BOND-III are trademarks of Leica Biosystems.